Logo image
Se connecter
O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial
Acte de colloque

O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial

M. Bourlière, P. Rabiega, N. Ganne-Carrie, L. Serfaty, P. Marcellin, Noëlle Pouget, D. Guyader, C. Hezode, Maurice Picon, X. Causse, …
The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver (Vienne, Austria, 22/04/2015)
2015

Fichiers et liens (1)

url
Find in HALAfficher

Indicateurs

1 Consultations de la notice

Détails

Logo image